141 Shares in ResMed Inc. (NYSE:RMD) Purchased by Ashton Thomas Securities LLC

Ashton Thomas Securities LLC acquired a new stake in ResMed Inc. (NYSE:RMD) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 141 shares of the medical equipment provider’s stock, valued at approximately $34,000.

A number of other institutional investors also recently modified their holdings of RMD. UMB Bank n.a. increased its holdings in shares of ResMed by 1.9% in the third quarter. UMB Bank n.a. now owns 2,465 shares of the medical equipment provider’s stock valued at $602,000 after purchasing an additional 47 shares in the last quarter. Dorsey & Whitney Trust CO LLC raised its position in shares of ResMed by 3.7% during the first quarter. Dorsey & Whitney Trust CO LLC now owns 1,473 shares of the medical equipment provider’s stock worth $292,000 after acquiring an additional 52 shares during the last quarter. QRG Capital Management Inc. lifted its stake in shares of ResMed by 4.5% during the second quarter. QRG Capital Management Inc. now owns 1,291 shares of the medical equipment provider’s stock valued at $247,000 after acquiring an additional 56 shares during the period. Inspire Advisors LLC boosted its holdings in ResMed by 1.9% in the second quarter. Inspire Advisors LLC now owns 3,060 shares of the medical equipment provider’s stock valued at $586,000 after acquiring an additional 56 shares during the last quarter. Finally, Concurrent Investment Advisors LLC increased its position in ResMed by 3.1% in the third quarter. Concurrent Investment Advisors LLC now owns 1,919 shares of the medical equipment provider’s stock worth $469,000 after purchasing an additional 57 shares during the period. 54.98% of the stock is owned by institutional investors.

ResMed Stock Performance

Shares of ResMed stock opened at $231.43 on Friday. The company has a debt-to-equity ratio of 0.13, a current ratio of 2.92 and a quick ratio of 1.91. The firm has a market cap of $33.97 billion, a price-to-earnings ratio of 30.65, a price-to-earnings-growth ratio of 1.81 and a beta of 0.69. The stock’s 50-day moving average is $243.30 and its 200-day moving average is $223.37. ResMed Inc. has a one year low of $147.31 and a one year high of $260.49.

ResMed (NYSE:RMD) last released its earnings results on Thursday, October 24th. The medical equipment provider reported $2.20 EPS for the quarter, beating the consensus estimate of $2.03 by $0.17. The firm had revenue of $1.22 billion for the quarter, compared to analysts’ expectations of $1.19 billion. ResMed had a return on equity of 25.53% and a net margin of 23.15%. The business’s quarterly revenue was up 11.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.64 EPS. Equities analysts predict that ResMed Inc. will post 9.22 earnings per share for the current fiscal year.

ResMed Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 12th. Investors of record on Thursday, November 7th will be given a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a yield of 0.92%. The ex-dividend date is Thursday, November 7th. ResMed’s dividend payout ratio (DPR) is currently 28.08%.

Insider Buying and Selling at ResMed

In related news, CFO Brett Sandercock sold 1,000 shares of ResMed stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $246.42, for a total value of $246,420.00. Following the sale, the chief financial officer now owns 96,812 shares of the company’s stock, valued at approximately $23,856,413.04. The trade was a 1.02 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel Michael J. Rider sold 882 shares of the stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $231.00, for a total value of $203,742.00. Following the transaction, the general counsel now directly owns 10,512 shares of the company’s stock, valued at $2,428,272. This trade represents a 7.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 63,056 shares of company stock worth $15,086,020. Insiders own 0.71% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. StockNews.com upgraded shares of ResMed from a “hold” rating to a “buy” rating in a research report on Tuesday, October 15th. Wolfe Research reaffirmed an “underperform” rating and issued a $180.00 price objective on shares of ResMed in a research note on Wednesday, September 18th. Royal Bank of Canada increased their price target on ResMed from $224.00 to $232.00 and gave the company a “sector perform” rating in a research note on Friday, October 25th. KeyCorp lifted their price objective on ResMed from $251.00 to $266.00 and gave the stock an “overweight” rating in a research note on Friday, October 25th. Finally, Bank of America upped their price objective on ResMed from $240.00 to $270.00 and gave the company a “buy” rating in a report on Thursday, September 26th. One analyst has rated the stock with a sell rating, five have given a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $225.70.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.